Fractyl Health stock plunges after $20 million public offering

Published 06/08/2025, 15:52
© Reuters.

Investing.com -- Fractyl Health Inc (NASDAQ:GUTS) stock plunged 47.3% after the metabolic therapeutics company announced the pricing of a $20 million public offering of common stock and warrants.

The offering consists of 19,047,619 shares of common stock, each accompanied by one Tranche A warrant with a 2-year term and one Tranche B warrant with a 5-year term. The combined public offering price is $1.05 per share and accompanying warrants.

Both warrant tranches have a fixed exercise price of $1.05 per share, with no variable pricing mechanisms or anti-dilution features. If fully exercised for cash, these warrants could generate up to an additional $40 million in future gross proceeds for the company.

Fractyl has also granted underwriters a 30-day option to purchase up to an additional 2,857,142 shares of common stock with associated warrants at the public offering price, less underwriting discounts and commissions.

The company, which focuses on developing treatments for obesity and type 2 diabetes, plans to use the proceeds to support its Revita and Rejuva pipeline programs, as well as for working capital and general corporate purposes.

Ladenburg Thalmann & Co. Inc. is serving as the book-running manager for the offering. The significant stock decline reflects investor concerns about potential dilution from the new share issuance.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.